CLAIMS

WHAT IS CLAIMED IS:

1. An isolated polypeptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 2, wherein amino acid residue 241 (numbered according to the EU index of Kabat) of the polypeptide, which corresponds to amino acid residue 32 of SEQ ID NO: 2, is an alanine (A), and wherein the isolated polypeptide exhibits binding to DC-SIGN and hFcγRIIB.

2. The isolated polypeptide of claim 1, wherein the amino acid sequence is at least 95% identical to SEQ ID NO: 2.

3. The isolated polypeptide of claim 1, wherein the amino acid sequence is at least 99% identical to SEQ ID NO: 2.

4. The isolated polypeptide of claim 1, wherein the polypeptide has the amino acid sequence according to SEQ ID NO: 2.

5. The isolated polypeptide of claim 1, wherein the polypeptide is sialylated.

6. The isolated polypeptide of claim 1, wherein the polypeptide is not sialylated.

7. A pharmaceutical composition, comprising (i) the isolated polypeptide of claim 1, and (ii) a pharmaceutically acceptable carrier.

8. An isolated polypeptide of claim 1 for use in therapy.

9. Use of an isolated polypeptide of claim 1 in the manufacture of a medicament for treating an inflammatory disorder in an individual in need thereof.

10. The use of claim 9, wherein the inflammatory disorder is an autoimmune disease.

11. The use of claim 9, wherein the inflammatory disorder is an inflammatory bowel disease, an inflammatory dermatosis, a hypersensitivity lung disease, or an acute or chronic inflammatory disease.

12. The use of claim 9, wherein the inflammatory disorder is psoriasis, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, lupus, type I diabetes, primary biliary cirrhosis, asthma, acute respiratory distress syndrome, fulminant hepatitis, myasthenia gravis, juvenile onset diabetes, glomerulonephritis, autoimmune thyroiditis, ankylosing spondylitis, systemic sclerosis, or Sjogren's syndrome.

13. The use of claim 11, wherein the inflammatory bowel disease is Crohn’s disease or ulcerative colitis.

14. The use of claim 11, wherein the inflammatory dermatosis is dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria, necrotizing vasculitis, cutaneous vasculitis, hypersensitivity vasculitis, eosinophilic myositis, polymyositis, dermatomyositis, or eosinophilic fasciitis.

15. The use of claim 11, wherein the hypersensitivity lung disease is hypersensitivity pneumonitis, eosinophilic pneumonia, delayed-type hypersensitivity, interstitial lung disease (ILD), idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis.

16. The use of claim 11, wherein the acute or chronic inflammatory disease is systemic anaphylaxia, allograft rejection, or graft-versus-host disease.